Close Menu

NEW YORK (GenomeWeb) – Albany Molecular Research (AMRI) announced it has obtained a non-exclusive license for CRISPR/Cas9 technology from the Broad Institute.

The contract research organization said in a statement that CRISPR offered "significant utility" for pharmaceutical research and development, especially drug target assessment, in vitro model development, and optimization. AMRI reported that it has already used CRISPR/Cas9 in both customer and internal R&D projects.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Wall Street Journal reports that Russia's announcement of a coronavirus vaccine approval was met with concern as safety testing has not yet been completed.

New Scientist writes there aren't much data available on the accuracy of the two rapid COVID-19 tests the UK plans to roll out.

In PNAS this week: downstream effect of oncoprotein fusion, epigenetic changes influence tRNAs in colon cancer, and more.

Nature News reports that recent proposed changes to the US National Science Foundation have raised concerns about a shift away from the agency's focus on basic research.